A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults

A Randomized, Open-label, 6-sequence, 3-period Crossover Clinical Trial to Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adult Volunteers.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07717775

Enrollment

Registered

2026-07-21

Start date

2026-08-01

Completion date

2026-11-01

Last updated

2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Brief summary

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.

Detailed description

The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-234 compared with AD-2341, AD-2342 in healthy subjects.

Interventions

DRUGAD-234

AD-234 tablet administered orally

DRUGAD-2341

AD-2341 tablet administered orally

DRUGAD-2342

AD-2342 tablet administered orally

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening * Body weight between 50.0 kg and 90.0 kg, inclusive, and body mass index (BMI) between 18.5 kg/m\^2 and 29.9 kg/m\^2, inclusive, at the time of screening (BMI = weight \[kg\] / height \[m\]\^2) * For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)

Exclusion criteria

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration Other exclusions applied

Design outcomes

Primary

Measure	Time frame
Percent of Time With Gastric pH ≥4 During the 24-hour Interval After the 7th Dose	From pre-dose (0h) on Day 7 to 24 hours post-dose on Day 7 of each treatment period (Period 1: Day 7-Day 8; Period 2: Day 28-Day 29; Period 3: Day 49-Day 50)

Countries

South Korea

Contacts

CONTACTJaeHun Jung

jhjung@addpharma.co.kr+82-31-891-5683

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026